Cardiovascular Area
The aim of the group is to contribute to identifying epigenetic modulators associated with the pathophysiology of cardiovascular diseases and their risk factors, with the aim of identifying new biomarkers and therapeutic targets that contribute to better stratification and a better approach to cardiovascular patients.
Research Lines
Chemotherapy cardiotoxicity
Breast cancer is the most prevalent in women globally. Advances in screening, early diagnosis, and therapeutic approaches in recent decades have led to a gradual increase in survival rates and life expectancy. This has highlighted the deleterious effect of long-term chemotherapy. We now know that cardiotoxicity is one of the most common complications associated with chemotherapy treatment and that cardiovascular disease is the leading cause of death among cancer survivors. Our objective is focused on the identification of new biological markers, which, together with the established echocardiographic parameters, allow a subclinical diagnosis of cardiac toxicity and a better stratification of the cancer patient, in addition to the identification of possible prevention and treatment routes in preclinical models.
Epigenetic modulators in cardiovascular disease.
MicroRNAs are small non-coding ribonucleic acid sequences (18-25nt) that play an essential role in gene expression at the post-transcriptional level. In recent years, the role of microRNAs in cardiovascular pathophysiology has attracted great interest. For this reason, in our group we have focused on studying its role in the pathophysiology of different cardiovascular diseases (heart failure, atrial fibrillation, amyloidosis, Brugada syndrome, etc.).
Members
Selected Results
Proposed mechanism of docetaxel induced cardiotoxicity: Involvement of ER stress. DTX induces BIP, CHOP, ATF6 expression and reduces GADD34 expression increasing phosphorylated eIF2a levels. Unresolved ER stress will eventually lead to cell death (caspase-mediated apoptosis). Rounded ends indicate inhibitory pathways; arrows indicate stimulatory pathways.
Spin-Offs
B-Flow offers exclusive technology in a personalized way to build Organ-on-a-chip models which that reproduce the in vivo conditions.
The innovative product is a digital report with personalized medicine indicators in cardiology to support diagnosis and treatment decision-making for patients with ischemic heart disease.
Alliances
